APOC3

Apolipoprotein C-III UniProt accession P02656

Component of triglyceride-rich very low density lipoproteins (VLDL) and high density lipoproteins (HDL) in plasma (PubMed:18201179, PubMed:22510806). Plays a multifaceted role in triglyceride homeostasis (PubMed:18201179, PubMed:22510806). Intracellularly, promotes hepatic very low density lipoprotein 1 (VLDL1) assembly and secretion; extracellularly, attenuates hydrolysis and clearance of triglyceride-rich lipoproteins (TRLs) (PubMed:18201179, PubMed:22510806).

Impairs the lipolysis of TRLs by inhibiting lipoprotein lipase and the hepatic uptake of TRLs by remnant receptors (PubMed:18201179, PubMed:22510806). Formed of several curved helices connected via semiflexible hinges, so that it can wrap tightly around the curved micelle surface and easily adapt to the different diameters of its natural binding partners (PubMed:18408013)

Source: UniProt
Secreted
Source: UniProt

Liver

Source: UniProt
  • Hyperalphalipoproteinemia 2 (HALP2)

    A condition characterized by high levels of high density lipoprotein (HDL) and increased HDL cholesterol levels.

Source: UniProt
  • Chylomicron assembly
  • Chylomicron remodeling
  • HDL remodeling
  • Retinoid metabolism and transport
Source: Reactome via UniProt

Mutations

No mutation information available.

Synthetic Lethal Network

Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to APOC3, aggregated across our SSL data sources. Click any partner node to view that gene’s page.

Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.

BioGRID SLOrth SynLethDB MexDrugs Multi-source
Sources: BioGRID, SLOrth, SynLethDB, MexDrugs

Clinical Trials

Total Trials Found: 18

NCT ID Condition Brief Title Phase Status
NCT06784349 Dyslipidemia ALN-APOC3 in Adult Participants With Dyslipidemia PHASE1 COMPLETED
NCT01682655 Fatty Liver, Obesity Genetic Variant in Apolipoprotein C3 Gene and Fatty Liver in Obese Children N/A COMPLETED
NCT04419688 Hypertriglyceridemia A First in Human Study of STT-5058, an Antibody That Binds ApoC3 PHASE1 TERMINATED
NCT04720534 Severe Hypertriglyceridemia Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia PHASE2 COMPLETED
NCT07176923 Familial Chylomicronemia Syndrome (FCS) CS-121 APOC3 Base Editing in FCS EARLY_PHASE1 RECRUITING
NCT05079919 Severe Hypertriglyceridemia A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia PHASE3 COMPLETED
NCT05902598 Familial Chylomicronemia Syndrome A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome PHASE3 COMPLETED
NCT04998201 Mixed Dyslipidemia Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia PHASE2 COMPLETED
NCT03783377 Hypertriglyceridemia, Familial Chylomicronemia Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS) PHASE1 COMPLETED
NCT02083510 Hypertriglyceridemia, Gout, Pericarditis Apolipoprotein CIII Reduction Via Colchicine EARLY_PHASE1 COMPLETED